Lopez L M, Mehta J L, Baz R, Aguila E
Clin Pharmacol Ther. 1984 Oct;36(4):444-50. doi: 10.1038/clpt.1984.202.
We compared the efficacy and safety of nitrendipine with that of hydralazine in 21 subjects with essential hypertension. Nitrendipine or hydralazine was given in a double-blind manner after a placebo period. Dose was titrated to diastolic blood pressure (BP) less than or equal to 90 mm Hg and the dose established during titration was continued for 5 to 7 wk. Both supine and erect BP were decreased by both drugs, but heart rate was affected only minimally. Myocardial oxygen demand decreased only with nitrendipine (P less than 0.05), although the change may have been the result of somewhat higher systolic BP while on placebo. Hydralazine induced minimal changes in levels of plasma catecholamines, but plasma norepinephrine levels rose in subjects on nitrendipine. Side effects encountered with both drugs were much the same, although nitrendipine was more often associated with mild fatigue. There were mild elevations in liver function parameters in two subjects on nitrendipine. There was little difference between the effects of nitrendipine and hydralazine in hypertension.
我们比较了尼群地平与肼屈嗪对21例原发性高血压患者的疗效和安全性。在经过安慰剂期后,以双盲方式给予尼群地平或肼屈嗪。剂量滴定至舒张压(BP)小于或等于90 mmHg,并将滴定期间确定的剂量持续5至7周。两种药物均使仰卧位和直立位血压降低,但对心率影响极小。仅尼群地平使心肌需氧量降低(P<0.05),尽管这种变化可能是由于服用安慰剂时收缩压略高所致。肼屈嗪使血浆儿茶酚胺水平变化极小,但服用尼群地平的患者血浆去甲肾上腺素水平升高。两种药物出现的副作用大致相同,尽管尼群地平更常伴有轻度疲劳。两名服用尼群地平的患者肝功能参数有轻度升高。尼群地平与肼屈嗪在治疗高血压方面的效果差异不大。